Loading...
Two recent prospective, randomized clinical trials in Norway were designed to assess cardiovascular risk reduction from supplementation with folic acid (0.8 mg/day) and vitamin B12 (0.4 mg/day), with or without vitamin B6 (40 mg/day), in patients with ischemic heart disease. As in other secondary-prevention trials, the supplements did not reduce cardiovascular events or mortality, but folic acid plus B12 was associated with a statistically nonsignificant increase in cancer rate over a mean of 39 months. This finding prompted the current analysis of data on 6837 patients followed for 3 years after the trials were completed.
During the trials and follow-up period, those randomized to folic acid plus vitamin B12 (but not B6) had an excess risk …